Aciont gets grant for macular degeneration study

The NIH and the National Eye Institute are backing new research to determine if a non-invasive technology can be used to deliver Avastin and Lucentis as a treatment for age-related macular degeneration. Aciont will use the $214,000 grant to study delivering the therapies with the Visulex ocular application. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.